Dhl Supply Chain Netherlands BV

To evaluate the efficacy and safety of lanariumab and icatibant in Chinese patients who received at least one dose of lanariumab or icatibant in real-world clinical practice.

Primary Objective: The primary objective of this study is to evaluate the safety of VPRIV by assessing the incidence of serious treatment-related adverse events (TEAEs) during treatment with EOW IV infusion in Chinese type 1 Gaucher disease subjects for up to 51 weeks. Secondary Objectives: The secondary objectives of this study are to evaluate: Other safety parameters of VPRIV (including the incidence of TEAEs and IRRs and the rate of antibody formation) Effect of VPRIV on hematological manifestations Effect of VPRIV on liver and spleen volumes Effect of VPRIV on QoL PK of VPRIV Effect of VPRIV on disease biomarkers

Primary objective: To evaluate the safety of Ripuga in Chinese Fabry disease naïve subjects by evaluating the incidence of treatment-emergent serious adverse events (TEAEs) throughout the study. Secondary objectives: 1. To evaluate other safety parameters of Ripuga; 2. To evaluate the efficacy of Ripuga on renal function parameters (estimated glomerular filtration rate [eGFR]); 1) To evaluate the efficacy of Ripuga on other renal function variables, pain, and pharmacodynamic (PD) markers (plasma lyso-Gb3); 2) To evaluate hearing changes in subjects aged <18 years; 3) To evaluate the pharmacokinetics (PK) of Ripuga in Chinese Fabry disease naïve subjects.